Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma

Journal of Clinical Pathology

Volumn 64, Issue 4, 2011, Pages 349-353

  Macher Goeppinger, Stephan ^a   Penzel, Roland ^a   Roth, Wilfried ^a   Dienemann, Hendrik ^b   Thomas, Michael ^b   Schnabel, Philipp Albert ^a   Schirmacher, Peter ^a   Bläker, Hendrik ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EXON; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BLASTOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BETA CATENIN; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; PULMONARY BLASTOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 79953091637     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.085696     Document Type: Article

References (35)

1. Moran CA, Suster S. Tumors of the lung and pleura. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors: Churchill Livingstone, 2007:181-214.
2. Colby TV, Koss MN, Travis WD. Pulmonary blastoma. In: Atlas of Tumor Pathology: Tumor of the Lower Respiratory Tract, 3rd series, Fascicle 13. Washington, DC: Armed Forces Institute of Pathology, 1995:395-417.
3. Nakatani Y, Masudo K, Miyagi Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol 2002;15:617-24. (Pubitemid 34666465)
4. Sekine S, Shibata T, Matsuno Y, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol 2003;200:214-21. (Pubitemid 36748030)
5. Larsen H, Sørensen JB. Pulmonary blastoma: a review with special emphasis on prognosis and treatment. Cancer Treat Rev 1996;22:145-60. (Pubitemid 26333835)
6. Sato S, Koike T, Yamato Y, et al. Resected well-differentiated fetal pulmonary adenocarcinoma and summary of 25 cases reported in Japan. Jpn J Thorac Cardiovasc Surg 2006;54:539-42. (Pubitemid 46154117)
7. Zagar TM, Blackwell S, Crawford J, et al. Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report. J Thorac Oncol 2010;5:282-3.
8. Mulamalla K, Truskinovsky AM, Dudek AZ. Pulmonary blastoma with renal metastasis responds to sorafenib. J Thorac Oncol 2007;2:344-7. (Pubitemid 47181719)
9. Takahashi K, Kohno T, Matsumoto S, et al. Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report. Lung Cancer 2007;57:103-8. (Pubitemid 46843334)
10. Hansen T, Bittinger F, Kortsik C, et al. Expression of KIT (CD117) in biphasic pulmonary blastoma. Novel data on histogenesis. Lung 2003;181:193-200. (Pubitemid 37176050)
11. Holst VA, Finkelstein S, Colby TV, et al. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis. Am J Surg Pathol 1997;21:801-11. (Pubitemid 27406550)
12. Nakatani Y, Miyagi Y, Takemura T, et al. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 2004;28:921-7. (Pubitemid 38856849)
13. Negri T, Casieri P, Miselli F, et al. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Br J Cancer 2007;96:180-1. (Pubitemid 46094661)
14. Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 2009;18:1735-51.
15. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28(Suppl 1):S32-7.
16. Kitaeva MN, Grogan L, Williams JP, et al. Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res 1997;57:4478-81. (Pubitemid 27441048)
17. Penzel R, Aulmann S, Moock M, et al. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005;58:634-9. (Pubitemid 40814026)
18. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51. (Pubitemid 30639518)
19. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90. (Pubitemid 27136715)
20. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-70.
21. Suzuki M, Shigematsu H, Nakajima T, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007;13:6087-92. (Pubitemid 350075066)
22. Tseng R, Lin R, Wen C, et al. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene 2008;27:4488-96.
23. Shigemitsu K, Sekido Y, Usami N, et al. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001;20:4249-57. (Pubitemid 32762199)
24. Proctor L, Folpe AL, Esper A, et al. Well-differentiated fetal adenocarcinoma of the lung: cytomorphologic features on fine-needle aspiration with emphasis on use of beta-catenin as a useful diagnostic marker. Diagn Cytopathol 2007;35:39-42. (Pubitemid 46095113)
25. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
26. Liegl-Atzwanger B, Fletcher JA, Fletcher CDM. Gastrointestinal stromal tumors. Virchows Arch 2010;456:111-27.
27. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
28. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
29. Papaetis GS, Syrigos KN. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev 2010;29:151-70.
30. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-47.
31. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
32. Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005;129:285-302. (Pubitemid 41002061)
33. Ji H, Wang J, Nika H, et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 2009;36:547-59.
34. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
35. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23. (Pubitemid 39665498)